Výsledky vyhledávání - "S. M. van Gastel"

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer

Autor: Maureen J.B. Aarts, F.W.P.J. van den Berkmortel, Birgit E.P.J. Vriens, D.J. van Spronsen, Vivianne C. G. Tjan-Heijnen, Petronella G. M. Peer, M. de Boer, Ingeborg J. H. Vriens, Tineke J. Smilde, L. J. C. van Warmerdam, S. M. van Gastel

Publikováno v: Breast Cancer Research and Treatment, 165, 3, pp. 593-600
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 165, 593-600
Breast Cancer Research and Treatment, 165(3), 593-600. Springer, Cham

Purpose The INTENS study was designed to determine whether delivering neoadjuvant chemotherapy at a higher dose in a shorter period of time improves outcome of breast cancer patients. Methods Women with newly diagnosed breast cancer were randomly ass

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::158e4312b701690587657c750dbd35a7
https://hdl.handle.net/2066/182883

Zobrazit plný text záznamu

Abstract P1-14-07: Neoadjuvant chemotherapy and pathologic complete response in relation to the clinical response, results from a phase III study (INTENS) of the Dutch breast cancer trialists' group (BOOG)

Autor: J. Wals, L. J. C. van Warmerdam, H.W.M. van Laarhoven, George F. Borm, Birgit E.P.J. Vriens, D.J. van Spronsen, Tineke J. Smilde, S. M. van Gastel, B. de Vries, Vcg Tjan-Heijnen

Publikováno v: Cancer Research. 72:P1-14

Background Taxanes have an established role as (neo-)adjuvant treatment of breast cancer. In the present study, we compared 4 AC–4 T with 6 cycles of TAC in the neoadjuvant setting (A = adriamycine, C = cyclophosphamide, T = docetaxel). Previously,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a6024c95491a4b96ce7224c6387c146b
https://doi.org/10.1158/0008-5472.sabcs12-p1-14-07

Zobrazit plný text záznamu

Abstract P3-15-01: Primary G-CSF Prophylaxis during the First Two Cycles Only or Throughout All Chemotherapy Cycles in Breast Cancer Patients at Risk of Febrile Neutropenia: Final Results from a Phase III Trial of the Dutch Breast Cancer Trialists Group (BOOG)

Autor: Ccd van der Rijt, Wmw Dercksen, Mjb Aarts, Yjl Kamm, Hwr Nortier, S. M. van Gastel, Alphons G.H. Kessels, Ljc van Warmerdam, Cmpw Mandigers, Manuela A. Joore, Vcg Tjan-Heijnen, Jacqueline M. Stouthard, F.P.J. Peters

Publikováno v: Cancer Research. 70:P3-15

Background: In patients at risk of febrile neutropenia (FN), the highest incidence of FN is seen during the first chemotherapy cycles. This observation questions the effectiveness of continued G-CSF prophylaxis during later chemotherapy cycles. Metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0cb4b1ffebc98269b63124f9c2021a6
https://doi.org/10.1158/0008-5472.sabcs10-p3-15-01

Zobrazit plný text záznamu

PD04-02: Recovery of Ovarian Function in Breast Cancer Patients with Chemotherapy-Induced Amenorrhea Receiving Anastrozole in the Dutch DATA Study

Autor: S. M. van Gastel, H de Graaf, J.W.R. Nortier, J. Wals, Caroline Seynaeve, Carolien H. Smorenburg, Aafke H. Honkoop, VC Tjan-Heijnen, Sangen M van der, Frans L. G. Erdkamp, George F. Borm

Publikováno v: Cancer Research. 71:PD04-02

Background: In early stage hormone receptor positive breast cancer, aromatase inhibitors (AIs) are established as adjuvant therapy for postmenopausal women. In daily practice AIs are also offered to patients with chemotherapy-induced amenorrhea (CIA)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f96eb3c89b6d54a0f7491c719e5da5a
https://doi.org/10.1158/0008-5472.sabcs11-pd04-02

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání